FLCCC to Merck: Data Shows Ivermectin’s Strong Efficacy Against COVID-19

FLCCC to Merck: Data Shows Ivermectin’s Strong Efficacy Against COVID-19

The Front Line COVID-19 Critical Care Alliance (FLCCC) has issued a public statement in response to a press release issued by Merck last week.

When the FLCCC Alliance reviewed the Merck release of February 4, 2021— which discounted the efficacy of ivermectin for the prevention and treatment of COVID-19— they were stunned by the fact that Merck provided no scientific data to support their conclusion. Additionally, the company’s absolute disregard for the most current medical evidence is an evidentiary indictment of their uncorroborated position. 

Furthermore, the FLCCC—with a lifesaving mission inspired by the imperatives to “put patients first” and to “follow the science”—believes that the pharmaceutical giant’s press release will cause governments, health authorities, medical providers, business leaders, and citizens to retreat from pursuing a medical agent that, according to our recent peer-reviewed and accepted publication to the highly regarded Frontiers in Pharmacology, has been proven to be an effective and globally available agent to prevent and treat every phase of COVID-19 disease. It is critical to note that with supplies of the vaccines running short—especial...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee